RT Journal Article SR Electronic T1 Vedolizumab-induced acute pancreatitis: the first reported clinical case JF BMJ Case Reports FD BMJ Publishing Group Ltd SP bcr-2017-222554 DO 10.1136/bcr-2017-222554 VO 2018 A1 Sherman Picardo A1 Kenji So A1 Kannan Venugopal A1 Marcus Chin YR 2018 UL http://casereports.bmj.com/content/2018/bcr-2017-222554.abstract AB Drug-induced acute pancreatitis (DIAP) is a rare, but clinically significant diagnosis. Vedolizumab, an α4β7 integrin inhibitor, which was approved in 2015 for treatment of moderate to severe inflammatory bowel disease, is a well-tolerated medication with a favourable safety profile and minimal serious adverse events in premarketing clinical trials. We present the first reported case of acute pancreatitis directly attributable to vedolizumab.